AstraZeneca

India approves AstraZeneca and local COVID vaccines, rollout in weeks

NEW DELHI (Reuters) - India's drugs regulator on Sunday gave final approval for the emergency-use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by…

Read More Here

AstraZeneca expects to supply 2 million doses of COVID-19 vaccine every week in UK

About two million doses of COVID-19 vaccine developed by Oxford University and AstraZeneca are set to be supplied every week by the middle of January in the United Kingdom, The…

Read More Here

EXPLAINER – How does AstraZeneca’s vaccine compare with Pfizer-BioNTech?

ZURICH, Dec 30 (Reuters) - Britain on Wednesday became the first country to approve AstraZeneca and Oxford University's home-grown UK COVID-19 vaccine, adding an easy-to-manage shot to the arsenal of…

Read More Here

Britain approves AstraZeneca/Oxford COVID-19 vaccine

LONDON, Dec 30 (Reuters) - Britain on Wednesday became the first country in the world to approve a coronavirus vaccine developed by Oxford University and AstraZeneca as it battles a…

Read More Here

Putin lauds AstraZeneca as it signs vaccine tie-up deal with Russia

MOSCOW (Reuters) - Russian President Vladimir Putin on Monday hailed British drugmaker AstraZeneca's decision to test combining its own experimental COVID-19 vaccine with Russia's Sputnik V shot, as Moscow said…

Read More Here

Suspected North Korean hackers targeted COVID vaccine maker AstraZeneca

Suspected North Korean hackers have tried to break into the systems of British drugmaker AstraZeneca in recent weeks, two people with knowledge of the matter told Reuters, as the company…

Read More Here

AstraZeneca CEO says smaller first dose in COVID-19 vaccine is ‘big plus’

AstraZeneca's chief executive officer Pascal Soriot said on Monday that the lower first dose of its experimental COVID-19 vaccine meant more people can be vaccinated more quickly, as the British…

Read More Here

AstraZeneca COVID-19 shot candidate shows promise among elderly in trials

A potential COVID-19 vaccine developed by AstraZeneca Plc and Oxford University produced a strong immune response in older adults, giving hope it may protect some of those most vulnerable to…

Read More Here

India’s Serum says produced 40 million doses of AstraZeneca COVID-19 vaccine

Serum Institute of India, the world's largest vaccine producer, said on Thursday it has made 40 million doses of AstraZeneca's potential COVID-19 vaccine, and would soon begin making Novavax's rival…

Read More Here

AstraZeneca’s cancer drug fails to meet main goal in COVID-19 trials

AstraZeneca Plc said on Thursday its blood cancer treatment, Calquence, failed to meet the main goal of mid-stage trials, testing it in patients hospitalized with respiratory symptoms of COVID-19. The…

Read More Here

Delivery timetable for Oxford/AstraZeneca vaccine slips, UK official says

The timetable for delivery of the Oxford University/AstraZeneca COVID-19 vaccine candidate has slipped, the UK's vaccine chief said, adding Britain will receive just 4 million doses of the shot this…

Read More Here

EU drug watchdog won’t set minimum efficacy levels for potential COVID-19 vaccines

Europe's drug regulator will not set a minimum level of efficacy for potential COVID-19 vaccines when considering them for approval, it said on Wednesday, taking a different approach to that…

Read More Here

Britain starts accelerated review for AstraZeneca’s potential COVID-19 vaccine

AstraZeneca Plc said on Sunday Britain's health regulator had started an accelerated review of its potential coronavirus vaccine. "We confirm the MHRA's (Medicines and Healthcare Products Regulatory Agency) rolling review…

Read More Here

Britain expects verdict on Pfizer’s COVID-19 vaccine before AstraZeneca’s

Senior sources in the British government expect that a verdict on whether Pfizer Inc-backed COVID-19 vaccine works will be available before the results are in on AstraZeneca Plc's competing vaccine,…

Read More Here

AstraZeneca says Oxford COVID-19 vaccine prompts immune response among adults old and young

The COVID-19 vaccine being developed by the University of Oxford produces a similar immune response in both older and younger adults, and adverse responses were lower among the elderly, British…

Read More Here

AstraZeneca COVID-19 vaccine trial Brazil volunteer dies but trial to continue

Brazilian health authority Anvisa said that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would…

Read More Here

U.S. trial of AstraZeneca COVID-19 vaccine may resume this week

AstraZeneca Plc's COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a…

Read More Here

AstraZeneca wins two approval recommendations from EU agency

The European medicines watchdog has recommended approving AstraZeneca Plc's treatments for a form of heart failure and a lung disorder, the British drugmaker said on Monday. The Committee for Medicinal…

Read More Here

Swiss to buy 5.3 mln doses of AstraZeneca COVID-19 vaccine

Switzerland signed a contract for up to 5.3 million doses of a potential COVID-19 vaccine being developed and tested by AstraZeneca and Oxford University, the Swiss government said on Friday.…

Read More Here

AstraZeneca could profit from COVID-19 vaccine as early as July

AstraZeneca could start profiting from its COVID-19 vaccine as soon as July next year, the Financial Times reported, citing a memo showing the British drugmaker can declare when it considers…

Read More Here

AstraZeneca resumes vaccine trial in Japan, in talks with U.S

AstraZeneca Plc said on Friday clinical trials of its experimental COVID-19 vaccine resumed in Japan, while adding that it was in talks with regulators on data needed to restart studies…

Read More Here

FDA widens U.S. safety inquiry into AstraZeneca coronavirus vaccine

The U.S. Food and Drug Administration has broadened its investigation of a serious illness in AstraZeneca Plc's COVID-19 vaccine study and will look at data from earlier trials of similar…

Read More Here

AstraZeneca gets partial immunity in low-cost EU vaccine deal

European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official…

Read More Here

AstraZeneca says COVID-19 vaccine trial in U.S still on hold

AstraZeneca Plc said that its COVID-19 vaccine trial in the United States is still on hold. AstraZeneca on Saturday published a document describing details of how the COVID-19 vaccine trial…

Read More Here

AstraZeneca’s trial illnesses may not be due to COVID-19 shot – Oxford University

The adverse events that led to a pause in trials evaluating AstraZeneca Plc's COVID-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining…

Read More Here

Italy could have AstraZeneca COVID-19 vaccine by end November

Italy could have its first shots of British drugmaker AstraZeneca's potential COVID-19 vaccine by the end of November, the managing director of IRBM told Reuters. Biotech firm IRBM, whose lab…

Read More Here

EU medical register shows AstraZeneca’s UK COVID-19 vaccine trials restarted

AstraZeneca's British clinical trials of its COVID-19 vaccine, one of the most advanced in development, resumed on Monday, according to the European clinical trials database EudraCT. The trial's status changed…

Read More Here

AstraZeneca vaccine trial pause a “wake-up call”, says WHO

AstraZeneca's pause of an experimental vaccine for the coronavirus after the illness of a participant is a "wake-up call" but should not discourage researchers, the World Health Organization's (WHO) chief…

Read More Here

AstraZeneca says should know if vaccine works by year-end if trials resume

AstraZeneca should still know before the end of the year whether its experimental vaccine protects people against COVID-19, the drugmaker's chief executive Pascal Soriot said on Thursday, as long as…

Read More Here

UK says other vaccine trials also likely to be paused

Other COVID-19 vaccine trials are likely to be paused at some point the British government’s Chief Scientific Adviser Patrick Vallance, said, describing a pause in the trial of an AstraZeneca…

Read More Here

Australia says not worried about AstraZeneca’s suspension of COVID vaccine trials

AstraZeneca Plc's suspension of its COVID-19 vaccine trials after a participant's unexplained illness did not mean the vaccine had been scrapped and showed safety standards were being adhered to, Australia's…

Read More Here

UPDATED: WHO says vaccine safety top priority, as AstraZeneca pauses study

Safety of a prospective vaccine for COVID-19 comes "first and foremost", the World Health Organization's chief scientist said on Wednesday, as a trial of a candidate from AstraZeneca was paused,…

Read More Here

UK health minister says pause in AstraZeneca vaccine trial not necessarily a setback

Britain's Health Secretary Matt Hancock said on Wednesday that AstraZeneca's decision to pause its coronavirus vaccine trials was a challenge but would not necessarily set back efforts to develop a…

Read More Here

AstraZeneca puts leading COVID-19 vaccine trial on hold over safety concern

AstraZeneca Plc announced it has paused a late-stage trial of one of the leading COVID-19 vaccine candidates after an unexplained illness in a study participant. "Our standard review process was…

Read More Here

Australia expects to receive AstraZeneca’s COVID-19 vaccine within months

Australia expects to receive its first batches of a potential COVID-19 vaccine in January, Prime Minister Scott Morrison said on Monday, as the number of new daily infections in the…

Read More Here

Astrazeneca to begin Phase 1/2 clinical trials of coronavirus vaccine in Japan

Astrazeneca said on Friday it is beginning Phase 1/2 clinical trials in Japan of its coronavirus vaccine candidate. Trials of the vaccine, known as AZD1222, will be conducted at multiple…

Read More Here

EU secures AstraZeneca’s potential COVID-19 vaccine

The European Commission has made a 336 million euro ($396 million) downpayment to British drug maker AstraZeneca to secure at least 300 million doses of its potential COVID-19 vaccine, a…

Read More Here

Argentina and Mexico to produce AstraZeneca COVID-19 vaccine

Argentina and Mexico will produce the AstraZeneca COVID-19 vaccine for most of Latin America, Argentine President Alberto Fernandez announced after a meeting with company executives involved in the project. An…

Read More Here

A look at AstraZeneca’s potential coronavirus vaccine

AstraZeneca signed its first COVID-19 vaccine supply deal with a Chinese company, Kangtai Bio, opening up distribution to one of the world's most populous countries. Drugmakers are racing to combat…

Read More Here

AstraZeneca to be exempted from coronavirus vaccine liability claims in most countries

AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries it has so far struck supply agreements with, a…

Read More Here

France expects AstraZeneca COVID-19 vaccine to be shared pro rata

A deal between AstraZeneca and France over potential COVID-19 vaccines foresees doses being split between countries on a pro-rata basis based on population, a source at the French President's office…

Read More Here

AstraZeneca in talks with Japan, Russia, Brazil and China on COVID-19 vaccine supplies

AstraZeneca is in talks with Japan, Russia, Brazil and China about supply deals for its potential coronavirus vaccine, its chief said on Saturday, as the British drugmaker prepares to publish…

Read More Here

AstraZeneca boosts potential supply to 2 billion in two deals involving Microsoft billionaire Bill Gates

British drugmaker AstraZeneca has doubled manufacturing capacity for its potential coronavirus vaccine to 2 billion doses in two deals involving Microsoft billionaire Bill Gates that guarantee early supply to lower income countries.…

Read More Here

AstraZeneca pilots diabetes drug as potential COVID-19 treatment

Britain’s AstraZeneca is testing a diabetes drug as a potential treatment for COVID-19 patients who also had existing heart and kidney problems, its second trial of an approved therapy to…

Read More Here

AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19

AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in…

Read More Here

World’s largest genetics project to tackle deadly diseases launched in the UK

A new ground-breaking project in the fight against life-threatening illnesses has launched today in the UK. The £200 million whole genome sequencing project is being created, forming a partnership of…

Read More Here

Successful trials for AstraZeneca’s blood cancer drug continue

AstraZeneca Plc announced its blood cancer drug met the primary endpoint of a final stage trial, the second success for the treatment in a month. The drug, Calquence, showed meaningful…

Read More Here